Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gjorgji Bozhinovski has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksandar Dimovski

    Research Centre for Genetic Engineering and Biotechnology “Georgi D Efremov”, Macedonian Academy of Sciences and Arts, 1000 Skopje, North Macedonia

    1 shared publication
  • Branislava Gemovic

    Department for Bioinformatics and Computational Chemistry, VINČA Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia

    1 shared publication
  • Dijana Plaseska-Karanfilska

    Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Science and Arts, Skopje, North Macedonia

    1 shared publication
  • Emilija Shukarova Stefanovska

    Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov’’, Macedonian Academy of Sciences and Arts, 1000 Skopje, North Macedonia

    1 shared publication
  • Iva Popović

    Center for Light-Based Research and Technologies COHERENCE, Department of Atomic Physics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia

    1 shared publication
  • Ivana Maleva Kostovska

    Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov’’, Macedonian Academy of Sciences and Arts, 1000 Skopje, North Macedonia

    1 shared publication

Latest Publications

  • Open Access

    Population-Specific Carrier Frequencies in an Underrepresented Genetically Heterogeneous Population: Implications for Expanded Carrier Screening

    by Predrag Noveski, Natalija Jovanovska, Ivana Maleva Kostovska, Gjorgji Bozhinovski, Sanja Kiprijanovska, Marija Terzikj, Marija Vujovikj, Emilija Shukarova Stefanovska, Aleksandar Dimovski, Dijana Plaseska-Karanfilska

    Background/Objectives: Expanded carrier screening (ECS) panels often rely on pan-ethnic databases, such as the ACMG Tier 3 panel, but their ability to capture population-specific reproductive risk is uncertain. We characterized pathogenic/likely pathogenic (P/LP) variants and at-risk-couple (ARC) probabilities in an underrepresented population from North Macedonia to inform ECS gene prioritization. Methods: NGS data from 1438 subjects of Macedonian, Albanian, and other local ancestry, referred for rare-disease diagnostics, were analyzed across 1795 candidate autosomal recessive/X-linked genes. P/LP variants were compared with gnomAD exomes v2.1.1 non-Finnish European frequencies (Fisher’s exact test). Gene-specific ARC probabilities ranked genes and generated cumulative ARC curves per subgroup. Results: We identified 2007 P/LP variants across 1096 genes. One hundred variants in 89 genes reached an allele frequency ≥ 1/200 in the Macedonian or Albanian subgroups; over one-third were absent from candidate ECS panels, mostly linked to severe or variable phenotypes. ARC saturated rapidly: genes with carrier counts ≥ 1/100 (ACMG Tier 2) accounted for over 85% of total ARC, and with ≥1/200 (ACMG Tier 3) for more than 93%. Total ARC among autosomal recessive panel genes (X-linked genes analyzed separately) was 3.42%, rising to 5.02% in the Albanian subgroup. Excluding top hypomorphic variants reduced ARC by 34–37%, highlighting variant-specific penetrance. The highest-ARC genes diverged between subgroups, with limited overlap with pan-ethnic panels. Conclusions: Population-specific carrier frequencies influence gene prioritization and estimated reproductive-risk probabilities for ECS. Population-tailored ECS panels that incorporate local carrier-frequency data, including embryonic/fetal-lethal genes, and account for hypomorphic alleles to avoid overestimating reproductive risk probabilities could improve the identification of couples at increased reproductive risk, particularly in underrepresented populations.

  • Open Access

    S-Doped Carbon Dot Treatment Alters RNA Processing, Translation, and Protein Degradation Pathways in HeLa Cells

    by Katarina Davalieva, Vanja Ralić, Gjorgji Bozhinovski, Branislava Gemović, Maja D. Nešić, Lela Korićanac, Tanja Dučić, Manuel Algarra, Iva A. Popović, Milutin Stepić, et al.

    Carbon dots offer excellent physico-chemical properties and biocompatibility for cancer theranostics systems, either as therapeutic agents themselves, or as potential drug carriers. It is, however, postulated that the drug carrier affects the mechanism of action and intracellular target molecules of a drug. Therefore, in the present study, we systematically evaluated protein alterations in HeLa cervical cancer cells after treatment with sulfur-doped carbon dots (S-CDs). Synchrotron Radiation μFTIR spectroscopy and label-free LC–MS/MS proteomics integrated with bioinformatics were used to assess molecular changes. μFTIR revealed a shift and increased intensity of α-helices, indicating structural changes in proteins as a result of the interaction between S-CDs and cells. Proteomic analysis identified 122 statistically significant (p ≤ 0.05) proteins with increased abundance and 61 with decreased abundance following S-CD exposure, many of which possess high α-helix content, consistent with μFTIR findings. Functional analyses showed that up-regulated proteins were enriched in molecular adaptor, transporter, and transcription regulator activities, particularly those involved in RNA metabolism and translation. Down-regulated proteins were dominated by protein-modifying enzymes and cytoskeletal components. Pathway enrichment analysis indicated alterations in mRNA processing, ribosomal pathways, translation factors, aminoacyl-tRNA biosynthesis, and proteasome degradation. Key hub proteins included ribosomal proteins and translation initiation factors. S-CD treatment led to opposite regulation of many proteins compared to their regulation in untreated HeLa cells including down-regulation of ribosomal proteins (RPS27L, RPS19, and RPS5), aminoacyl-tRNA biosynthesis proteins (IARS1, LARS1, and MARS1), and proteasome degradation proteins (PSMD2, PSMD3, and PSMD11), which aligns with the observed cytotoxic effect of S-CDs on cervical cancer cells. Overall, these results highlight significant proteomic and structural protein changes induced by S-CDs and support their potential for cervical cancer treatment, warranting further investigation of this nanomaterial’s biological applications.